In this phase II randomized trial with 3-year follow-up, perioperative toripalimab plus chemotherapy significantly improved event-free survival and overall survival compared to chemotherapy alone in patients with locally advanced gastric or gastroesophageal junction cancer. The combination also reduced the rate of metastasis and relapse, particularly peritoneal metastasis, establishing it as a promising treatment option in this setting.
Study
|
Randomized, open-label, phase II trial [NEOSUMMIT-01, NCT04250948] |
| Locally advanced gastric or gastroesophageal junction cancer |
| Toripalimab plus chemotherapy (n=54) vs chemotherapy alone (n=54). 3 cycles pre-op and 5 cycles post-op treatment
|
Efficacy
|
EFS at 3 years: 74.7% vs 56.2% (HR 0.51 [0.27-0.98]) |
| OS at 3 years: 81.3% vs 72.2% (HR 0.45 [0.21-0.95])
|
Safety
|
Not reported in the manuscript
|
J Clin Oncol. Published online 2026-05-05
http://doi.org/10.1200/JCO-25-02842
Reviewed by Ulas D. Bayraktar, MD on May 15, 2026
